上 海 证 券 交 易 所 上证公监函〔2023〕0215 号 关于对上海新世界股份有限公司及有关责任人 予以监管警示的决定 当事人： 上海新世界股份有限公司，A 股证券简称：新世界，A 股证券代 码：600628； 吴胜军，上海新世界股份有限公司时任财务总监； 马炳芳，上海新世界股份有限公司时任董事会秘书。 经查明，根据上海新世界股份有限公司（以下简称新世界或公 司）于 2023 年 8 月 31 日披露的公告，公司于 2011 年 7 月 8 日和其 控股股东上海新世界（集团）有限公司（以下简称新世界集团）及 其下属子公司共同出资 10,000 万元人民币成立了上海申城通商务 有限公司（以下简称申城通商务）。其中，新世界集团出资 3,500 万元，持有申城通商务 35%的股权；新世界集团下属 7 家子公司合 计出资 5,500 万元，持有申城通商务 55%的股权；公司出资 1,000 万元，持有申城通商务 10%的股权。 根据公司公告，本次交易构成关联交易，相关交易金额占公司 2010 年经审计净资产绝对值的 0.52%，但公司未就该关联交易事项 及时履行董事会审议程序及信息披露义务，迟至 2023 年 ...

证券代码：600628 简称：新世界 公告编号：临 2023-039 上海新世界股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 9 月 18 日（星期一）至 9 月 22 日（星期五）下午 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 xsj600628@163.com 进行提问。公司将在 2023 年半年度业绩说明会上对投 资者普遍关注的问题进行回答。 上海新世界股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日 在上海证券交易所网站（http://www.sse.com.cn）披露了《公司 2023 年 半年度报告》，为便于广大投资者更全面深入地了解公司 2023 年半年度经 营成果、财务状况，公司计划于 2023 年 9 月 25 日（星期一）下午 15:00-16:00 召开 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥532.32 million, a 59.46% increase compared to ¥333.84 million in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2023 was ¥38.03 million, representing a significant increase of 218.77% from a loss of ¥32.02 million in the previous year[20]. - The net cash flow from operating activities improved to ¥152.25 million, a 196.88% increase from a negative cash flow of ¥157.16 million in the same period last year[20]. - The basic earnings per share for the first half of 2023 was ¥0.06, compared to a loss of ¥0.05 per share in the same period last year, marking a 220.00% increase[21]. - The weighted average return on equity increased by 1.64 percentage points to 0.90% compared to -0.74% in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥24.70 million, an increase of 144.67% from a loss of ¥55.29 million in the same period last year[20]. - The company's total operating revenue for the first half of 2023 reached 532.32 million RMB, a significant increase from 333.84 million RMB in the same period of 2022, reflecting a growth rate of 59.6%[27]. - The company's operating costs rose by 28.28% to CNY 327.88 million, up from CNY 255.60 million year-on-year[41]. Asset and Equity Management - The company's net assets attributable to shareholders at the end of the reporting period were ¥4.25 billion, a slight increase of 0.92% from ¥4.21 billion at the end of the previous year[20]. - Total assets decreased by 1.04% to ¥5.66 billion from ¥5.72 billion at the end of the previous year[20]. - Cash and cash equivalents increased by 37.09% to CNY 1.77 billion, up from CNY 1.29 billion at the end of the previous period[44]. - The company's total liabilities decreased to CNY 1,404,708,898.51 from CNY 1,504,018,868.42, reflecting a reduction of about 6.61%[95]. - The total equity attributable to shareholders rose to CNY 4,246,784,647.29 from CNY 4,208,100,410.95, marking an increase of approximately 0.92%[95]. Market and Sales Performance - The company reported a significant recovery in its retail, hotel, and pharmaceutical sales, contributing to the overall revenue growth[21]. - The gross profit margin for the department store segment improved to 38.41% in the first half of 2023, compared to 23.44% in the same period of 2022[27]. - The revenue from self-operated sales of traditional Chinese medicine reached 149.48 million RMB, with a gross profit margin of 32.51%, up from 31.03% in the previous year[28]. - The hotel segment reported a revenue of 63.92 million RMB with a gross profit margin of 53.10%, a significant increase from 22.11 million RMB in the same period of 2022[27]. - The total retail sales of consumer goods in Shanghai for the first half of 2023 amounted to 937.76 billion RMB, representing a year-on-year growth of 23.5%[29]. Strategic Initiatives and Market Expansion - The company has introduced new brands focused on subculture and hosted the "2023 New World ACG Carnival" to enhance market differentiation and engagement[35]. - The company is actively pursuing market expansion and innovative marketing strategies to increase its market share in the hotel industry[35]. - The overall market for the health industry, particularly traditional Chinese medicine, is expected to continue growing due to increasing consumer demand and supportive government policies[31]. - The company has introduced new products targeting the "Z Generation" consumer group, including anime and gaming merchandise, to capture market share[39]. - The company is focusing on high-quality development and consumer promotion as part of its strategic initiatives for sustainable growth[38]. Financial Management and Governance - The company emphasizes the importance of monitoring investment risks related to forward-looking statements in its reports[4]. - The company has made changes in its board of directors, including the election of new independent and employee directors, which may impact governance and strategic direction[57]. - The company's financial management team is led by CFO Wang Wenhua, indicating a focus on maintaining financial stability and transparency[108]. - The company’s board is chaired by Mr. Chen Yong, emphasizing strong leadership in navigating market challenges[108]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions in accordance with government regulations, focusing on peak shaving for electricity demand[65]. - The company conducts annual emissions testing for natural gas boiler exhaust and monthly water quality testing for wastewater discharge[63]. - The company has established emergency response plans for environmental incidents, including gas leaks and boiler emergencies[64]. - The company has committed to avoiding competition with its subsidiaries and ensuring fair treatment of shareholders[67]. Risks and Challenges - The company faces risks from macroeconomic fluctuations and a slowdown in retail growth, with significant pressure on performance due to a "macro heat, micro cold" situation in the economy[52]. - Increased competition in the retail sector and policy changes are expected to further pressure the company's market position, particularly in the pharmaceutical sales segment[53]. - Rising operational costs and declining profit margins are concerns, driven by increased minimum wage standards and fluctuations in raw material prices[54]. - The company is navigating a challenging retail environment, with online retail competition affecting traditional sales channels and profit margins[53]. Investment and Subsidiary Performance - The company reported a net profit of 1,289.44 million RMB from Shanghai Cai Tong De Pharmaceutical Co., Ltd., while other subsidiaries showed varying performance, with some reporting losses[51]. - The company has completed a capital increase for its subsidiary, Shanghai Cai Tong De Pharmaceutical Co., bringing in two external strategic partners to strengthen its health industry[39]. - The company has established several new subsidiaries, including Shanghai New World Radisson Hotel Co., Ltd. with an investment of ¥24,700,000.00 and Shanghai New World Investment Consulting Co., Ltd. with an investment of ¥159,000,000.00[46]. Accounting and Financial Reporting - The company follows the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position and operating results[1]. - The company recognizes cash and cash equivalents as highly liquid investments that can be readily converted to known amounts of cash[10]. - The company applies the equity method for accounting investments in joint ventures and recognizes its share of the joint venture's assets and liabilities[8]. - The company recognizes revenue based on the assessment of contracts, identifying performance obligations, and allocating transaction prices accordingly[182]. - The company has implemented changes in accounting policies effective January 1, 2023, related to deferred tax assets and liabilities, impacting financial reporting[196].

证券代码：600628 证券简称：新世界 公告编号：临2023-034 上海新世界股份有限公司 关于子公司上海徐重道中药饮片有限公司 完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2022 年 12 月 9 日，上海新世界股份有限公司（以下简称"公司"）召开了十一届八次 董事会、十一届八次监事会会议，审议通过了《关于子公司上海徐重道中药饮片有限公司 拟增资扩股的议案》，同意公司全资子公司上海蔡同德药业有限公司（以下简称"蔡同德 药业"）子公司上海徐重道中药饮片有限公司（以下简称"徐重道公司"）通过在上海联合 产权交易所公开挂牌方式进行增资扩股，征集不超过 2 家外部战略合作伙伴。详见公司于 2022 年 12 月 10 日在上海证券交易所网站（http://www.sse.com.cn）披露的《关于子公 司上海徐重道中药饮片有限公司拟增资扩股的公告》（临 2022-041）。 名称：上海徐重道中药饮片有限公司 类型：其他有限责任公司 法定代表人：杨琦晖 注册资本：人民币 500.0000 ...

证券代码：600628 证券简称：新世界 公告编号：2023-033 上海新世界股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.03 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/17 | － | 2023/8/18 | 2023/8/18 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2023 年 6 月 28 日的 2022 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本646,875,384股为基数，每股派发现金红利0.03 元（含税），共计 ...

上海新世界股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600628 证券简称：新世界 公告编号：临 2023-023 重要内容提示： 会议召开时间：2023 年 6 月 9 日（星期五）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 报 · 中 国 证 券 网 （ 网 址 ： https://roadshow.cnstock.com/） 会议召开方式：视频录播结合网络文字互动 投资者可于 2023 年 6 月 8 日（星期四）下午 16:00 前将有关问题通过电 子邮件的形式发送至公司董事会办公室邮箱 xsj600628@163.com，公司将在 2022 年度业绩说明会上对投资者普遍关注的问题进行回答。 上海新世界股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 在上海证券交易所网站（http://www.sse.com.cn）披露了《公司 2022 年 年度报告》，为便于广大投资者更全面深入地了解公司 202 ...

证券代码：600628 证券简称：新世界 公告编号：临2023-022 上海新世界股份有限公司 关于举办"走进上市公司"投资者交流活动情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海新世界股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日下午举办了"走 进上市公司"投资者交流活动。本次活动旨在加强公司与投资者的沟通交流，让更多的投 资者近距离了解公司，增进上市公司市场认同和价值实现，提高上市公司质量。 现将本次活动的主要情况公告如下： 一、交流活动基本情况 时间：2023 年 5 月 29 日下午 2:00 形式：现场接待 调研机构：申万宏源证券 接待人：公司董事长陈湧先生，副董事长、总经理沈为民先生，副总经理、董事会秘 书、财务总监王文华女士，新世界城副总经理、品牌招商部经理李蔚先生，董办等相关人 员 二、交流活动的主要问题及回复 1、想请教公司酒店板块和零售板块整体回暖情况如何，针对接下来的零售业态有无 一些战略打法上的调整？ 答：2023 年春节之后，随着整体经济运行回暖向好的积极态势，顾 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥264,600,085.39, representing a year-on-year increase of 26.12%[4] - The net profit attributable to shareholders for the same period was ¥23,908,709.70, showing a significant increase of 127.82% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥16,248,978.83, with a remarkable growth of 439.94%[4] - Basic and diluted earnings per share were both ¥0.04, reflecting a 100% increase compared to the same period last year[4] - Operating profit for Q1 2023 was ¥26,257,891.36, significantly up from ¥3,139,373.28 in Q1 2022, marking an increase of 736.5%[14] - Net profit for Q1 2023 was ¥24,051,209.70, compared to ¥10,589,789.99 in Q1 2022, representing an increase of 127.5%[14] - The total comprehensive income for Q1 2023 was ¥24,767,756.35, compared to ¥8,576,859.80 in Q1 2022, an increase of 189.5%[14] Cash Flow - The net cash flow from operating activities was -¥13,743,271.34, indicating a decline of 67.76% year-on-year[4] - In Q1 2023, the cash inflow from operating activities was CNY 311,264,279.75, an increase of 14.94% compared to CNY 270,769,924.64 in Q1 2022[16] - The net cash flow from operating activities was -CNY 13,743,271.34, an improvement from -CNY 42,623,752.45 in the same period last year[16] - The cash inflow from investment activities totaled CNY 1,146,584,879.44, up from CNY 1,054,399,517.81 in Q1 2022, marking an increase of 8.73%[16] - The net cash flow from investment activities was CNY 417,829,348.76, significantly higher than CNY 13,981,266.81 in Q1 2022[16] - The cash inflow from financing activities was CNY 250,000,000.00, down from CNY 300,000,000.00 in Q1 2022, a decrease of 16.67%[16] - The net cash flow from financing activities was -CNY 54,464,714.62, worsening from -CNY 7,671,865.81 in the previous year[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,657,644,378.82, a decrease of 1.01% from the end of the previous year[4] - Total liabilities decreased to ¥1,421,417,804.76 in Q1 2023 from ¥1,504,018,868.42 in Q1 2022, a reduction of 5.5%[12] - Current liabilities totaled ¥1,393,670,052.42 in Q1 2023, down from ¥1,475,749,786.99 in Q1 2022, reflecting a decrease of 5.6%[12] - The total non-current assets were RMB 3,518,923,568.23, a slight decrease from RMB 3,526,145,646.18[11] - The total assets of the company as of March 31, 2023, were RMB 5,657,644,378.82, down from RMB 5,715,539,279.37[11] Shareholder Information - The top shareholder, Shanghai Huangpu District State-owned Assets Supervision and Administration Commission, holds 20.73% of the shares, totaling 134,074,446 shares[9] - Shanghai Zongyi Holdings Co., Ltd. is the second-largest shareholder with 13.07% ownership, amounting to 84,524,934 shares[9] Other Financial Metrics - The weighted average return on equity rose by 0.33 percentage points to 0.57%[4] - The company reported a significant reduction in trading financial assets, which decreased to RMB 157,500,000.00 from RMB 592,000,000.00[11] - The inventory decreased to RMB 144,248,825.30 from RMB 161,074,560.04, reflecting a decline of approximately 10.4%[11] - The company reported a decrease in financial expenses to ¥3,539,261.93 in Q1 2023 from ¥7,552,361.23 in Q1 2022, a reduction of 53.1%[14] - Other income for Q1 2023 was ¥96,720.63, down from ¥140,992.07 in Q1 2022, a decrease of 31.4%[14] Strategic Outlook - The company has not disclosed any significant new strategies or future outlook in the provided documents[10]

Financial Performance - The company's operating revenue for 2022 was ¥850.02 million, a decrease of 27.07% compared to ¥1,165.55 million in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥52.02 million, representing a decline of 174.90% from a profit of ¥69.46 million in 2021[20]. - The net cash flow from operating activities was ¥22.78 million, down 91.23% from ¥259.75 million in the previous year[20]. - The total assets at the end of 2022 were ¥5.72 billion, a decrease of 6.47% from ¥6.11 billion at the end of 2021[20]. - The company reported a basic earnings per share of -¥0.08 for 2022, a decrease of 172.73% from ¥0.11 in 2021[21]. - The weighted average return on equity was -1.21% for 2022, down 2.81 percentage points from 1.60% in 2021[21]. - The company reported a total profit of -59.57 million yuan, a decline of 152.47% compared to the previous year[55]. - The gross profit margin for department store joint sales was 47.78%, down from 67.91% in the previous year[47]. - The gross profit margin for self-operated pharmaceutical sales was 33.67%, compared to 27.78% in 2021[48]. - The company reported a net profit margin of 8% for 2022, with a goal to improve this to 10% in the next fiscal year[103]. Revenue Breakdown - The operating revenue from department stores was 212.93 million yuan, down 36.50% year-on-year[54]. - The pharmaceutical sales revenue reached 525.92 million yuan, while hotel services revenue was 47.85 million yuan, reflecting decreases of 16.76% and 48.32% respectively[54]. - Total revenue from Shanghai decreased by 27.03% to ¥835,704,543.42, with a gross margin reduction of 10.28 percentage points to 26.84%[60]. - The company achieved total operating revenue of 850.02 million yuan in 2022, a decrease of 27.07% compared to the previous year[54]. - The company’s total revenue for 2022 was CNY 850 million, with department store revenue at CNY 213 million and pharmaceutical revenue at CNY 526 million, together accounting for 86.92% of total revenue[166]. Cash Flow and Investments - The net cash flow from operating activities was 22.78 million yuan, a significant drop of 91.23% year-on-year[57]. - The company's cash flow from investment activities increased by 157.80% to ¥372,256,936.85, driven by higher cash inflows from redemptions exceeding purchases[65]. - The company reported a net cash outflow from financing activities of -¥265,697,320.45, a 142.19% increase in outflow due to debt repayment[65]. - The cash flow from investing activities showed a net inflow of CNY 372,256,936.85, a recovery from a net outflow of CNY 644,080,176.21 in 2021[190]. - The total cash inflow from investment activities in 2022 was 5,199,732,361.89 RMB, compared to 4,214,939,109.21 RMB in 2021, resulting in a net cash flow of 400,673,455.02 RMB[192]. Market Challenges and Strategies - The company faced significant challenges in the Shanghai consumer market, leading to a substantial decline in customer traffic and sales[22]. - The company expanded marketing efforts and introduced new brands to improve performance, but faced additional operational challenges in December 2022[22]. - The overall economic environment in China showed a GDP growth of 3% in 2022, with retail sales declining by 0.2%, impacting the company's performance[28]. - The company is addressing challenges in the retail sector, including declining sales and changing consumer habits, by adapting its strategies accordingly[85]. - Increased market competition and policy changes in the retail sector are anticipated to further pressure the company's sales performance[93]. Social Responsibility and Employee Welfare - The company implemented a rent reduction policy, providing over ¥40 million in rent relief to small and micro enterprises and individual businesses[22]. - The company actively engaged in social responsibility initiatives, including providing support for pandemic-related efforts and implementing rent reductions for small businesses[32]. - The company increased employee benefits, including meal subsidies and additional health check-up items, to improve employee welfare and engagement[37]. - Total investment in social responsibility projects amounted to 2.481 million RMB, with 1.781 million RMB in cash donations and 700,000 RMB in material donations[129]. Corporate Governance and Shareholder Engagement - The company has maintained compliance with legal and regulatory requirements regarding corporate governance, ensuring transparency in information disclosure[102]. - The board of directors and supervisory board consist of qualified members, with a focus on maintaining independence and avoiding conflicts of interest[102]. - The company has established measures to balance the expectations of stakeholders, including shareholders, customers, and employees, to promote sustainable development[102]. - The total compensation for senior management during the reporting period amounted to 459.24 million yuan, with the highest individual compensation being 75 million yuan[102]. - The company has not faced any penalties from securities regulatory authorities in the past three years[107]. Future Outlook and Strategic Initiatives - The company aims to enhance its position in the Shanghai international consumer center and maintain its leadership in the Nanjing Road commercial area[83]. - The health consumption market is experiencing accelerated growth, driven by increased health awareness and supportive government policies, creating new economic growth points[80]. - The company plans to focus on the transformation of department store formats and the integration of consumption and experience in 2023[84]. - The company is investing heavily in R&D, allocating 500 million RMB for the development of new technologies and products in the upcoming year[104]. - Future outlook indicates a projected revenue growth of 12% for 2023, driven by new product launches and market expansion strategies[104].

上海新世界股份有限公司（600628）2022 年第三季度报告 证券代码：600628 证券简称：新世界 上海新世界股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真实、准 确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 | | | | | 单位：元 币种：人民币 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上年 | | | | 增减变动幅度(%) | | 同期增减变动幅度(%) | | 营业收入 | 247,599,865.81 | -12.49 | 581,437,386.21 ...